nach oben

Erschienen in:

15.04.2019 | Original Paper

RETRACTED ARTICLE: Cancer-derived exosomal miR-221-3p promotes angiogenesis by targeting THBS2 in cervical squamous cell carcinoma

verfasst von: Xiang-Guang Wu, Chen-Fei Zhou, Yan-Mei Zhang, Rui-Ming Yan, Wen-Fei Wei, Xiao-Jing Chen, Hong-Yan Yi, Luo-Jiao Liang, Liang-sheng Fan, Li Liang, Sha Wu, Wei Wang

Erschienen in: Angiogenesis | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Abstract

Aims

Recently, cancer-derived exosomes were shown to have pro-metastasis function in cancer, but the mechanism remains unclear. Angiogenesis is essential for tumor progression and is a great promising therapeutic target for advanced cervical cancer. Here, we investigated the role of cervical cancer cell-secreted exosomal miR-221-3p in tumor angiogenesis.

Methods and results

miR-221-3p was found to be closely correlated with microvascular density in cervical squamous cell carcinoma (CSCC) by evaluating the microvascular density with immunohistochemistry and miR-221-3p expression with in situ hybridization in clinical specimens. Using the groups of CSCC cell lines (SiHa and C33A) with miR-221-3p overexpression and silencing, the CSCC exosomes were characterized by electron microscopy, western blotting, and fluorescence microscopy. The enrichment of miR-221-3p in CSCC exosomes and its transfer into human umbilical vein endothelial cells (HUVECs) were confirmed by qRT-PCR. CSCC exosomal miR-221-3p promoted angiogenesis in vitro in Matrigel tube formation assay, spheroid sprouting assay, migration assay, and wound healing assay. Then, exosome intratumoral injection indicated that CSCC exosomal miR-221-3p promoted tumor growth in vivo. Thrombospondin-2 (THBS2) was bioinformatically predicted to be a direct target of miR-221-3p, and this was verified by using the in vitro and in vivo experiments described above. Additionally, overexpression of THBS2 in HUVECs rescued the angiogenic function of miR-221-3p.

Conclusions

Our results suggest that CSCC exosomes transport miR-221-3p from cancer cells to vessel endothelial cells and promote angiogenesis by downregulating THBS2. Therefore, CSCC-derived exosomal miR-221-3p could be a possible novel diagnostic biomarker and therapeutic target for CSCC progression.

Nur mit Berechtigung zugänglich

Shrestha AD, Neupane D, Vedsted P, Kallestrup P (2018) Cervical cancer prevalence, incidence and mortality in low and middle income countries: a systematic review. Asian Pac J Cancer Prevent 19(2):319–324

Li H, Wu X: Advances in diagnosis and treatment of metastatic cervical cancer. 2016, 27(4):e43

Jayson GC, Kerbel R, Ellis LM, Harris AL (2016) Antiangiogenic therapy in oncology: current status and future directions. Lancet 388(10043):518–529CrossRef

Tewari KS, Sill MW, Long HJ, Penson RT, Huang H, Ramondetta LM, Landrum LM, Oaknin A, Reid TJ, Leitao MM et al (2014) Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med 370(8):734–743CrossRef

Alldredge JK, Tewari KS (2016) Clinical trials of antiangiogenesis therapy in recurrent/persistent and metastatic cervical cancer. Oncologist 21(5):576–585CrossRef

Symonds RP, Gourley C, Davidson S, Carty K, McCartney E, Rai D, Banerjee S, Jackson D, Lord R, McCormack M et al (2015) Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Oncol 16(15):1515–1524CrossRef

Svensson KJ, Belting M (2013) Role of extracellular membrane vesicles in intercellular communication of the tumour microenvironment. Biochem Soc Trans 41(1):273–276CrossRef

van den Boorn JG, Dassler J, Coch C, Schlee M, Hartmann G (2013) Exosomes as nucleic acid nanocarriers. Adv Drug Deliv Rev 65(3):331–335CrossRef

Zhang X, Yuan X, Shi H, Wu L, Qian H, Xu W (2015) Exosomes in cancer: small particle, big player. J Hematol Oncol 8:83CrossRef

10.

Falcone G, Felsani A, D’Agnano I (2015) Signaling by exosomal microRNAs in cancer. J Exp Clin Cancer Res 34:32CrossRef

11.

Kong YW, Ferland-McCollough D, Jackson TJ, Bushell M (2012) microRNAs in cancer management. Lancet Oncol 13(6):e249–e258CrossRef

12.

Wei WF, Zhou CF, Wu XG, He LN, Wu LF, Chen XJ, Yan RM, Zhong M, Yu YH, Liang L et al (2017) MicroRNA-221-3p, a TWIST2 target, promotes cervical cancer metastasis by directly targeting THBS2. Cell Death Dis 8(12):3220CrossRef

13.

Zhou W, Fong MY, Min Y, Somlo G, Liu L, Palomares MR, Yu Y, Chow A, O’Connor ST, Chin AR et al (2014) Cancer-secreted miR-105 destroys vascular endothelial barriers to promote metastasis. Cancer Cell 25(4):501–515CrossRef

14.

Hirsch FR, Varella-Garcia M, Bunn PA Jr, Di Maria MV, Veve R, Bremmes RM, Baron AE, Zeng C, Franklin WA (2003) Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 21(20):3798–3807CrossRef

15.

Wei WF, Han LF, Liu D, Wu LF, Chen XJ, Yi HY, Wu XG, Zhong M, Yu YH, Liang L et al (2017) Orthotopic xenograft mouse model of cervical cancer for studying the role of MicroRNA-21 in promoting lymph node metastasis. Int J Gynecol Cancer 27(8):1587–1595CrossRef

16.

Zhou CF, Ma J, Huang L, Yi HY, Zhang YM, Wu XG, Yan RM, Liang L, Zhong M, Yu YH et al (2018) Cervical squamous cell carcinoma-secreted exosomal miR-221-3p promotes lymphangiogenesis and lymphatic metastasis by targeting VASH1. Oncogene 38:1256–1268CrossRef

17.

Thery C, Amigorena S, Raposo G, Clayton A (2006) Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr Protoc Cell Biol Chap. 3:Unit 3.22

18.

Chan YK, Zhang H, Liu P, Tsao SW, Lung ML, Mak NK, Ngok-Shun Wong R, Ying-Kit Yue P (2015) Proteomic analysis of exosomes from nasopharyngeal carcinoma cell identifies intercellular transfer of angiogenic proteins. Int J Cancer 137(8):1830–1841CrossRef

19.

Nowak-Sliwinska P, Alitalo K, Allen E, Anisimov A, Aplin AC, Auerbach R, Augustin HG, Bates DO, van Beijnum JR, Bender RHF et al (2018) Consensus guidelines for the use and interpretation of angiogenesis assays. Angiogenesis 21:425–532

20.

Maracle CX, Kucharzewska P, Helder B, van der Horst C, Correa de Sampaio P, Noort AR, van Zoest K, Griffioen AW, Olsson H, Tas SW (2017) Targeting non-canonical nuclear factor-kappaB signalling attenuates neovascularization in a novel 3D model of rheumatoid arthritis synovial angiogenesis. Rheumatology 56(2):294–302CrossRef

21.

Li L, Li C, Wang S, Wang Z, Jiang J, Wang W, Li X, Chen J, Liu K, Li C et al (2016) Exosomes derived from hypoxic oral squamous cell carcinoma cells deliver miR-21 to normoxic cells to elicit a prometastatic phenotype. Cancer Res 76(7):1770–1780CrossRef

22.

Huang TH, Chu TY (2014) Repression of miR-126 and upregulation of adrenomedullin in the stromal endothelium by cancer-stromal cross talks confers angiogenesis of cervical cancer. Oncogene 33(28):3636–3647CrossRef

23.

Yang P, Chen N, Yang D, Crane J, Huang B, Dong R, Yi X, Guo J, Cai J, Wang Z (2017) Cervical cancer cell-derived angiopoietins promote tumor progression. Tumour Biol 39(7):1010428317711658CrossRef

24.

Hoff PM, Machado KK (2012) Role of angiogenesis in the pathogenesis of cancer. Cancer Treatm Rev 38(7):825–833CrossRef

25.

Tomao F, Papa A, Rossi L, Zaccarelli E, Caruso D, Zoratto F, Benedetti Panici P, Tomao S (2014) Angiogenesis and antiangiogenic agents in cervical cancer. OncoTargets Therapy 7:2237–2248CrossRef

26.

Kalluri R (2016) The biology and function of exosomes in cancer. J Clin Invest 126(4):1208–1215CrossRef

27.

Garcia-Donas J, Beuselinck B, Inglada-Perez L, Grana O, Schoffski P, Wozniak A, Bechter O, Apellaniz-Ruiz M, Leandro-Garcia LJ, Esteban E et al (2016) Deep sequencing reveals microRNAs predictive of antiangiogenic drug response. JCI Insight 1(10):e86051CrossRef

28.

Gramantieri L, Fornari F, Callegari E, Sabbioni S, Lanza G, Croce CM, Bolondi L, Negrini M (2008) MicroRNA involvement in hepatocellular carcinoma. J Cell Mol Med 12(6a):2189–2204CrossRef

29.

Nicoli S, Knyphausen CP, Zhu LJ, Lakshmanan A, Lawson ND (2012) miR-221 is required for endothelial tip cell behaviors during vascular development. Dev cell 22(2):418–429CrossRef

30.

Urbich C, Kuehbacher A, Dimmeler S (2008) Role of microRNAs in vascular diseases, inflammation, and angiogenesis. Cardiovasc Res 79(4):581–588CrossRef

31.

Milane L, Singh A, Mattheolabakis G, Suresh M, Amiji MM (2015) Exosome mediated communication within the tumor microenvironment. J Control Release 219:278–294CrossRef

32.

Meehan K, Vella LJ (2016) The contribution of tumour-derived exosomes to the hallmarks of cancer. Crit Rev Clin Lab Sci 53(2):121–131CrossRef

33.

Streit M, Riccardi L, Velasco P, Brown LF, Hawighorst T, Bornstein P, Detmar M (1999) Thrombospondin-2: a potent endogenous inhibitor of tumor growth and angiogenesis. Proc Natl Acad Sci USA 96(26):14888–14893CrossRef

34.

Simantov R, Febbraio M, Silverstein RL (2005) The antiangiogenic effect of thrombospondin-2 is mediated by CD36 and modulated by histidine-rich glycoprotein. Matrix Biol 24(1):27–34CrossRef

35.

Koch M, Hussein F, Woeste A, Grundker C, Frontzek K, Emons G, Hawighorst T (2011) CD36-mediated activation of endothelial cell apoptosis by an N-terminal recombinant fragment of thrombospondin-2 inhibits breast cancer growth and metastasis in vivo. Breast Cancer Res Treatm 128(2):337–346CrossRef

36.

Kyriakides TR, Leach KJ, Hoffman AS, Ratner BD, Bornstein P (1999) Mice that lack the angiogenesis inhibitor, thrombospondin 2, mount an altered foreign body reaction characterized by increased vascularity. Proc Natl Acad Sci USA 96(8):4449–4454CrossRef

37.

Yang Y, Li H, Ma Y, Zhu X, Zhang S, Li J (2018) MiR-221-3p is down-regulated in preeclampsia and affects trophoblast growth, invasion and migration partly via targeting thrombospondin 2. Biomed Pharmacother 109:127–134CrossRef

38.

Umezu T, Tadokoro H, Azuma K, Yoshizawa S, Ohyashiki K, Ohyashiki JH (2014) Exosomal miR-135b shed from hypoxic multiple myeloma cells enhances angiogenesis by targeting factor-inhibiting HIF-1. Blood 124(25):3748–3757CrossRef

39.

Hsu YL, Hung JY, Chang WA, Lin YS, Pan YC, Tsai PH, Wu CY, Kuo PL (2017) Hypoxic lung cancer-secreted exosomal miR-23a increased angiogenesis and vascular permeability by targeting prolyl hydroxylase and tight junction protein ZO-1. Oncogene 36(34):4929–4942CrossRef

40.

Bao L, You B, Shi S, Shan Y, Zhang Q, Yue H, Zhang J, Zhang W, Shi Y, Liu Y et al: Metastasis-associated miR-23a from nasopharyngeal carcinoma-derived exosomes mediates angiogenesis by repressing a novel target gene TSGA10. 2018, 37(21):2873–2889

41.

Garofalo M, Romano G, Di Leva G, Nuovo G, Jeon YJ, Ngankeu A, Sun J, Lovat F, Alder H, Condorelli G et al (2011) EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers. Nat Med 18(1):74–82CrossRef

42.

Teixeira AL, Dias F, Ferreira M, Gomes M, Santos JI, Lobo F, Mauricio J, Machado JC, Medeiros R (2014) Combined influence of EGF + 61G> A and TGFB + 869T> C functional polymorphisms in renal cell carcinoma progression and overall survival: the link to plasma circulating MiR-7 and MiR-221/222 expression. PloS ONE 10(4):e0103258CrossRef

43.

de Conti A, Ortega JF, Tryndyak V, Dreval K, Moreno FS, Rusyn I, Beland FA, Pogribny IP (2017) MicroRNA deregulation in nonalcoholic steatohepatitis-associated liver carcinogenesis. Oncotarget 8(51):88517–88528CrossRef

44.

Yoon S, Kovalenko A, Bogdanov K, Wallach D (2017) MLKL, the protein that mediates necroptosis, also regulates endosomal trafficking and extracellular vesicle generation. Immunity 47(1):51–65.e57CrossRef

45.

Zhou X, Zhang W, Yao Q, Zhang H, Dong G, Zhang M, Liu Y, Chen JK, Dong Z (2017) Exosome production and its regulation of EGFR during wound healing in renal tubular cells. Am J Phys Renal Physiol 312(6):F963–Ff970CrossRef

Titel: RETRACTED ARTICLE: Cancer-derived exosomal miR-221-3p promotes angiogenesis by targeting THBS2 in cervical squamous cell carcinoma
verfasst von: Xiang-Guang Wu
Chen-Fei Zhou
Yan-Mei Zhang
Rui-Ming Yan
Wen-Fei Wei
Xiao-Jing Chen
Hong-Yan Yi
Luo-Jiao Liang
Liang-sheng Fan
Li Liang
Sha Wu
Wei Wang
Publikationsdatum: 15.04.2019
Verlag: Springer Netherlands
Erschienen in: Angiogenesis / Ausgabe 3/2019
Print ISSN: 0969-6970
Elektronische ISSN: 1573-7209
DOI: https://doi.org/10.1007/s10456-019-09665-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

RETRACTED ARTICLE: Cancer-derived exosomal miR-221-3p promotes angiogenesis by targeting THBS2 in cervical squamous cell carcinoma

Abstract

Aims

Methods and results

Conclusions

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin

Springer Medizin

Abstract

Aims

Methods and results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2019

Cancer stem cells contribute to angiogenesis and lymphangiogenesis in serous adenocarcinoma of the ovary

The plaque-aortic ring assay: a new method to study human atherosclerosis-induced angiogenesis

Exhaustion of the bone marrow progenitor cell reserve is associated with major events in severe limb ischemia

A new prognostic model for survival in second line for metastatic renal cell carcinoma: development and external validation

Anti-secretogranin III therapy of oxygen-induced retinopathy with optimal safety

Monitoring tumour microenvironment changes during anti-angiogenesis therapy using functional MRI

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin